Skip to content

Designed to achieve a significant therapeutic advantage, our current pipeline explores AAV-mediated approaches, novel immunomodulation strategies, and dual routes of administration.

Discovery Preclinical Phase I Phase II Commercial

As we move forward, expect to see a diversified pipeline, including emerging technologies that will be evaluated for their potential to target underlying disease and help bring groundbreaking genetic therapies to more patients